GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Cash Flow from Financing

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Cash Flow from Financing : $31.94 Mil (TTM As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2015, Tribute Pharmaceuticals Canada paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.38 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.77 Mil on other financial activities. In all, Tribute Pharmaceuticals Canada earned $0.39 Mil on financial activities for the three months ended in Sep. 2015.


Tribute Pharmaceuticals Canada Cash Flow from Financing Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada Cash Flow from Financing Chart

Tribute Pharmaceuticals Canada Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 -0.02 2.97 5.51 31.17

Tribute Pharmaceuticals Canada Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.86 5.62 2.69 23.23 0.39

Tribute Pharmaceuticals Canada Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Tribute Pharmaceuticals Canada's Cash from Financing for the fiscal year that ended in Dec. 2014 is calculated as:

Tribute Pharmaceuticals Canada's Cash from Financing for the quarter that ended in Sep. 2015 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tribute Pharmaceuticals Canada  (OTCPK:TBUFF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Tribute Pharmaceuticals Canada's issuance of stock for the three months ended in Sep. 2015 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Tribute Pharmaceuticals Canada's repurchase of stock for the three months ended in Sep. 2015 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Tribute Pharmaceuticals Canada's net issuance of debt for the three months ended in Sep. 2015 was $-0.38 Mil. Tribute Pharmaceuticals Canada spent $0.38 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Tribute Pharmaceuticals Canada's net issuance of preferred for the three months ended in Sep. 2015 was $0.00 Mil. Tribute Pharmaceuticals Canada paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Tribute Pharmaceuticals Canada's cash flow for dividends for the three months ended in Sep. 2015 was $0.00 Mil. Tribute Pharmaceuticals Canada received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Tribute Pharmaceuticals Canada's other financing for the three months ended in Sep. 2015 was $0.77 Mil. Tribute Pharmaceuticals Canada received $0.77 Mil on other financial activities.


Tribute Pharmaceuticals Canada Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Traded in Other Exchanges
N/A
Address
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
John M Gregory director, 10 percent owner
Sj Strategic Investments Llc 10 percent owner
Joan P Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory other: Member 340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines